ABCB5+ MSCs have already demonstrated therapeutic efficacy in clinical trials in chronic skin wounds and in recessive dystrophic epidermolysis bullosa (14, 15). This evidence concerns the gene ABCB5 and recessive dystrophic epidermolysis bullosa inversa.